Preparation And Storage
Recommended Assay Procedures
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).
Product Notices
- This antibody was developed for use in flow cytometry.
- The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
- Researchers should determine the optimal concentration of this reagent for their individual applications.
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
- BD Horizon Brilliant Ultraviolet 395 is covered by one or more of the following US patents: 8,158,444; 8,575,303; 8,354,239.
Companion Products
The LpMab-23 monoclonal antibody specifically recognizes a cancer-specific form of human podoplanin. Podoplanin is a 38-44 kDa type I transmembrane glycoprotein that is encoded by PDPN. This heavily glycosylated mucin type protein is named for its expression on kidney glomerular epithelial cells known as podocytes. Although the podoplanin protein is expressed on a wide variety of cell types in normal tissues (including placenta, lung, skeletal muscle and brain), LpMab-23 recognizes an altered glycosylation pattern that occurs on oral cancer cells and it shows minimal reactivity with the surrounding non-cancerous tissue. In contrast, the LpMab-17 monoclonal antibody recognizes a non-glycosylated epitope of podoplanin on normal and cancer cells. Podoplanin induces platelet aggregation via its three platelet aggregation-stimulating (PLAG) domains; it binds C-type lectin domain family 1 member B (Clec1B, also known as CLEC2); and it is involved in actin cytoskeleton organization and in cellular adhesion and migration. It also plays roles in organogenesis, vascular development, inflammatory diseases, tumorigenesis, and cancer cell motility and metastasis.
The antibody was conjugated to BD Horizon™ BUV395 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye has been exclusively developed by BD Biosciences to have minimal spillover into other detectors, making it an optimal choice for multicolor flow cytometry. With an Ex Max at 348 nm and an Em Max at 395 nm, BD Horizon BUV395 can be excited with a 355 nm laser and detected with a 379/28 filter.
Development References (8)
-
Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer.. Front Immunol. 2012; 3:283. (Biology). View Reference
-
Chang JE, Turley SJ. Stromal infrastructure of the lymph node and coordination of immunity. Trends Immunol.. 2015; 36(1):30-9. (Biology). View Reference
-
Dang Q, Liu J, Li J, Sun Y. Podoplanin: a novel regulator of tumor invasion and metastasis. Med Oncol. 2014; 31(9):24. (Biology). View Reference
-
Miyazaki A, Nakai H, Sonoda T, et al. LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer. Oncotarget. 2018; 9(30):21156-21165. (Clone-specific: Immunohistochemistry). View Reference
-
Pan Y, Xia L. Emerging roles of podoplanin in vascular development and homeostasis. Front Med. 2015; 9(4):421-30. (Biology). View Reference
-
Retzbach EP, Sheehan SA, Nevel EM, et al. Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target. j.oraloncology. 2018; 78:126-136. (Clone-specific: Immunohistochemistry). View Reference
-
Ugorski M, Dziegiel P, Suchanski J. Podoplanin - a small glycoprotein with many faces. Am J Cancer Res. 2016; 6(2):370-86. (Biology). View Reference
-
Yamada S, Ogasawara S, Kaneko MK, Kato Y. LpMab-23: A Cancer-Specific Monoclonal Antibody Against Human Podoplanin. Monoclon Antib Immunodiagn Immunother. 2017; 36(2):72-76. (Immunogen: Flow cytometry, Immunohistochemistry). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.